Heart Failure Clinical Trial
Effects of Dark Chocolate on Exercise Capacity, and Mitochondrial Structure and Function
Summary
The major goal of this study is to characterize the ability of dark chocolate enriched in epicatechin (a component of dark chocolate) to improve the structural and functional features of mitochondria in two groups
Patients with heart failure (HF) and type 2 diabetes (DM2) and
Normal yet sedentary individuals with impaired baseline exercise capacity (as assessed by VO2 max)
We propose that a 3 month treatment with dark chocolate will lead to a significant improvement in exercise capacity which will be secondary to the improvement in skeletal muscle structure from epicatechin.
Full Description
The flavanol epicatechin (which is derived from cocoa and has no known toxicity in humans) has been shown in clinical trials to increase levels of nitric oxide (NO) as assessed by flow-mediated dilation (FMD) in the brachial artery and measurements of circulating NO in plasma. NO is thought to be an activator of PGC-1 alpha [PPAR (peroxisome proliferator-activated receptor) alpha coactivator 1] which stimulates mitochondrial biogenesis. In both patients with heart failure and diabetes there is nitric oxide deficiency and mitochondrial dysfunction. In our proposed double-blinded placebo controlled clinical trial, we will test the hypothesis that chronic administration of epicatechin to patients with both heart failure and diabetes will increase levels of NO and PGC-1 alpha leading to increased mitochondrial biogenesis and improved mitochondrial function. We believe similar changes will occur in sedentary individuals.
In a preliminary study with 5 patients with heart failure and diabetes (conducted under UCSD IRB protocol number #090688) we have shown that epicatechin enriched dark chocolate improves mitochondrial structure (Taub PR, Ramirez-Sanchez I, Ciaraldi TP, et al. Alterations in Skeletal Muscle Indicators of Mitochondrial Structure and Biogenesis in Patients with Type 2 Diabetes and Heart Failure: Effects of Epicatechin Rich Cocoa. Clin Transl Sci. 2011;5(1):43-47.)
Eligibility Criteria
Healthy, sedentary individuals:
Inclusion Criteria:
Healthy, inactive individuals
BMI 27-32
Exclusion Criteria:
Smoking or quit smoking less than 1 year prior to enrollment
Currently taking Coumadin or Pradaxa.
Heart failure and diabetes patients:
Inclusion Criteria:
Medically diagnosed with heart failure and diabetes
No significant HbA1C fluctuations in past 6 months
Exclusion Criteria:
Currently taking Insulin
Currently taking Coumadin or Pradaxa.
Smoking or quit smoking less than 1 year prior to enrollment
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There is 1 Location for this study
La Jolla California, 92093, United States
How clear is this clinincal trial information?

Please confirm you are a US based health care provider:
Yes, I am a health care Provider No, I am not a health care providerSign Up Now.
Take Control of Your Disease Journey.
Sign up now for expert patient guides, personalized treatment options, and cutting-edge insights that can help you push for the best care plan.